OncoMatch/Clinical Trials/NCT05156060
Gabapentin & Ketamine for Prevention/Treatment of Acute/Chronic Pain in Locally Advanced Head and Neck Cancer
Is NCT05156060 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including Gabapentin and Ketamine for head and neck cancer.
Treatment: Gabapentin · Ketamine — This is a study to establish a safe and feasible dose for prophylactic use of a combination of gabapentin and ketamine in head and neck cancer patients undergoing chemoradiation.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage T3N0M0, T4N0M0, T1N1M0, T2N1M0, T3N1M0, T4N1M0, T1N2M0, T2N2M0, T3N2M0, T4N2M0, T1N3M0, T2N3M0, T3N3M0, T4N3M0 (TNM)
Locally advanced non-metastatic disease (T3N0M0, T4N0M0, T1-4N1-3M0)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Lab requirements
Kidney function
glomerular filtration rate <30 mL/min/1.73 m2 [excluded]
Glomerular filtration rate <30 mL/min/1.73 m2
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Vanderbilt-Ingram Cancer Center · Nashville, Tennessee
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05156060 currently recruiting?
Yes, this trial is currently recruiting patients.
What disease stage is eligible?
Stage T3N0M0 or T4N0M0 or T1N1M0 or T2N1M0 or T3N1M0 or T4N1M0 or T1N2M0 or T2N2M0 or T3N2M0 or T4N2M0 or T1N3M0 or T2N3M0 or T3N3M0 or T4N3M0 is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages